Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ANTIVIRALS

Financiado

Cerrado

European Training Network on Antiviral Drug Development

Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed on... ver más

30/09/2019

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-09-30

MSCA-ITN-2014-ETN: Marie Skłodowska-Curie Innovative T... Scope:European Training Networks (ETN)

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

510.75K€ | Lider

LASURGAL

374.11K€ | Participante

INGAPAN

497.39K€ | Participante

INNOLACT

390.51K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-21617-C02-01 PROGRAMA DE INVESTIGACION ANTIVIRAL VIH-VHC 121K€ Cerrado

MAD-CoV 2 Modern approaches for developing antivirals against SARS CoV... 6M€ Cerrado

NAVIPP New AntiVirals for Infections with Pandemic Potential 6M€ Cerrado

HIT HIDDEN HIV Paving the way towards HIV eradication control 7M€ Cerrado

BIO2016-78746-C2-1-R IDENTIFICACION Y OPTIMIZACION DE INHIBIDORES DE LA GEMACION... 188K€ Cerrado

EU4HIVCURE Accelerating HIV Cure in Europe 329K€ Cerrado

Duración del proyecto: 57 meses Fecha Inicio: 2014-12-10
Fecha Fin: 2019-09-30

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens. Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development. The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary. ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry. Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores